Dosing & Uses
Prevention of Respiratory Syncytial Infection
Pending FDA approval for prevention of respiratory syncytial infection (RSV) in adults aged ≥60 years
Next:
Pharmacology
Mechanism of Action
Bivalent vaccine composed of equal amounts of recombinant RSV prefusion F from subgroups A and B
Crystal structure of prefusion F is a key form of the viral fusion protein (F) that RSV uses to enter human cells; antibodies specific to the prefusion form have shown to be highly effective at blocking virus infection, therefore, a prefusion F-based vaccine may confer optimal protection against RSV
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
